Dietary Cholesterol Absorption Inhibitor [EPC]

64369 reported adverse events

Drugs of this class: EZETIMIBE EZETIMIBE AND SIMVASTATIN ROSUVASTATIN AND EZETIMIBE (EZETIMIBE AND ATORVASTATIN) BEMPEDOIC ACID AND EZETIMIBE

These side effects are most commonly reported by patients taking drugs of the Dietary Cholesterol Absorption Inhibitor [EPC] class:

# Side effect Count
0 NAUSEA 3782
1 FATIGUE 3723
2 MYALGIA 3372
3 DRUG INEFFECTIVE 3337
4 DIZZINESS 2991
5 DYSPNOEA 2908
6 DIARRHOEA 2869
7 HEADACHE 2544
8 PAIN 2539
9 ASTHENIA 2450
See all common reactions for Dietary Cholesterol Absorption Inhibitor [EPC]

Drugs of the Dietary Cholesterol Absorption Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 HYPER IGE SYNDROME 50 0.5618
1 TRUNCUS ARTERIOSUS PERSISTENT 52 0.3133
2 TYPE IIA HYPERLIPIDAEMIA 46 0.3026
3 LOW DENSITY LIPOPROTEIN ABNORMAL 46 0.1207
4 AMAUROSIS FUGAX 64 0.0970
5 RESTRICTIVE PULMONARY DISEASE 80 0.0907
6 LOW DENSITY LIPOPROTEIN DECREASED 84 0.0833
7 LOW DENSITY LIPOPROTEIN INCREASED 443 0.0791
8 DIAPHRAGMATIC DISORDER 47 0.0730
9 CARDIAC SEPTAL DEFECT 41 0.0721
See all enriched reactions for Dietary Cholesterol Absorption Inhibitor [EPC]